Skip to main content

Table 1 Baseline characteristics of subjects

From: Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials

 

Overall

eGFR (mL/min/1.73 m2)

90

60 to <90

30 to <60

P value

Number of subjects

852

99

525

228

 

Age (years)

68.6 ± 8.1

63.7 ± 7.4

68.0 ± 7.7

72.1 ± 7.7

<0.0001*

Sex (male/female)

32/820

5/94

21/504

6/222

0.5110**

Daily/Weekly

604/248

63/36

350/175

191/37

<0.0001**

BMI (kg/m2)

22.2 ± 3.1

21.3 ± 2.8

22.0 ± 2.9

22.9 ± 3.3

<0.0001*

Lumbar spine BMD (g/cm2)

0.67 ± 0.09

0.67 ± 0.08

0.67 ± 0.09

0.67 ± 0.08

0.7043*

  1. Values are mean ± SD
  2. *F test, **Chi square test